Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Key Points

• Tirzepatide improves heart failure outcomes in patients with preserved ejection fraction, tackling chronic kidney disease.
• Key evidence shows improved outcomes for heart failure management with tirzepatide in an obesity cohort.
• Observational analysis across populations with chronic kidney disease evaluates the role of tirzepatide.
• This suggests potential shifts in treatment strategies for patients with concurrent chronic kidney disease and heart failure.